Mental health problems, psychotropic drug technologies and risk

Health, Risk and Society

Volumn 6, Issue 4, 2004, Pages 361-375

  Busfield, Joan ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Drug approval; Prescribing; Psychotropic drug technologies; Risk benefit assessments

Indexed keywords

AMITRIPTYLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; HYPNOTIC AGENT; IMIPRAMINE; MEPROBAMATE; METHYLPHENIDATE; PSYCHOTROPIC AGENT; RESERPINE;

ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG RESEARCH; DRUG UTILIZATION; HUMAN; IMPOTENCE; MEDICAL DECISION MAKING; MENTAL DISEASE; MOTOR DYSFUNCTION; PATIENT CARE; PRESCRIPTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOMNOLENCE; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 11444265543     PISSN: 13698575     EISSN: None     Source Type: Journal    
DOI: 10.1080/13698570412331323243     Document Type: Article

References (38)

1. Abraham, J. and Sheppard, J. (1999) The Therapeutic Nightmare: The Battle over the World's Most Controversial Sleeping Pill (London, Earthscan).
2. AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, The Lancet, 363, pp. 2105-2115.
3. Aparasu, A., Mort, J.R., Pharm, D. and Brandt, H. (2003) Psychotropic prescription use by community-dwelling elderly in the United States, Journal of the American Geriatrics Society, 51, pp. 671-677.
4. Beck, U. (1992) The Risk Society: Towards a New Modernity (London, Sage).
5. Bodenheimer, T. (2000) Uneasy alliance: clinical investigators and the pharmaceutical industry, New England Journal of Medicine, 342, pp. 1539-1544.
6. Busfield, J. (2002) Psychiatric disorder and individual violence: imagined death, risk and mental health policy, in: A. Buchanan (Ed) Care of the Mentally Disordered Offender in the Community, (Oxford, Oxford University Press).
7. Busfield, J. (2003) Globalization and the pharmaceutical industry revisited, International Journal of Health Services, 33, 581-605.
8. Cohen, J.S. (2001) Overdose: The Case against the Drug Companies (New York, Putnam).
9. Crombie, D.L. (1986) Classification of mental illness for primary care, in: M. Shepherd, G. Wilkinson and P. Williams (Eds) Mental Illness in Primary Care Settings (London, Tavistock).
10. Department of Health (2000) Prescriptions Dispensed in the Community, Statistics for 1989 to 1999: England, Statistical Bulletin 2000/2 (London, Department of Health).
11. Department of Health (2003) Prescriptions Dispensed in the Community, Statistics for 1992 to 2002: England (London, Department of Health).
12. Douglas, M. (1986) Risk Acceptability according to the Social Sciences (London, Routledge & Kegan Paul).
13. Douglas. M. (1992) Risk and Blame: Essays in Cultural Theory (London, Routledge).
14. M. Douglas, and A. Wildavsky (1982) Risk and Culture (berkeley, University of California Press).
15. ESEMED/MHEDEA 2000 (2004) 'Psychotropic drug utilization in Europe: Results from the European study of the epidemiology of mental disorder (ESEMeD) project,' Acta Psychiatrica Scandanavica, 109, pp. 55-64.
16. European Commission, Health & Consumer Protection Directorate-General (2002) Compulsory Admission and Involuntary Treatment of Mentally Ill Patients: Legislation and Practice in EU-member States (European Commission).
17. Furniss, L. (2002) Use of medicines in nursing homes for older people, Advances in Psychiatric Treatment, 8, pp. 198-204.
18. Furniss, L., Burns, A. and Panter, L. (2000) Effects of a pharmacist's medication review in nursing homes. Randomised control trial, British Journal of Psychiatry, 176, pp. 563-567.
19. Giddens, A. (1991) Modernity and Self-Identity: Self and Society in the Late Modern Age (Cambridge, Polity).
20. Harrison, A. (2003) Getting the Right Medicines? (London, Kings Fund).
21. Healy, D. (2002) The Creation of Psychopharmacology (Cambridge, Mass., Harvard University Press).
22. Hollingshead, A.B. and Redlich, F.C. (1958) Social Class and Mental Illness (New York, John Wiley).
23. Horwitz. A. (2000) Creating Mental Illness (Chicago, University of Chicago Press).
24. Hull, S.A., Cornwell, J., Harvey, C., Eldridge, S. and Omo Bare, P. (2001) Prescribing rates for psychotropic medication amongst east London general practices: low rates where Asian populations are greatest, Family Practice, 18, pp. 167-173.
25. Hunter, R. and Macalpine, I. (1963) Three Hundred Years of Psychiatry, 1535-1860 (London, Oxford University Press).
26. Independent Steering Committee (2004) Report of an Independent Review of Access to the Yellow Card Scheme (London, The Stationery Office).
27. Kjaegard, L.L. and Als-Nielson, B. (2002) Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ, British Medical Journal, 325, pp. 249-252.
28. Lexchin, J., Bero, L.A., Djulbegovic, B. and Clark, O. (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review, British Medical Journal, 326, pp. 1167-1173.
29. McCue, R.E., Waheed, R. and Urcuyo, L. (2003) Polypharmacy in patients with schizophrenia, Journal of Clinical Psychiatry, 64, pp. 984-989.
30. Moncrieff, J. (2003) Clozapine v conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination, British Journal of Psychiatry, 183, pp. 161-166.
31. NHS Centre for Reviews and Dissemination (1999) Drug Treatments of Schizophrenia, Effective Health Care, 5, No 6.
32. Ohayon, M.M. and Lader, M.H. (2002) Use of psychotropic medication in the general population of France, Germany, Italy and the United Kingdom, Journal of Clinical Psychiatry, 63, pp. 817-825.
33. Pearce, N. (1996) Adverse reactions, social responses: a tale of two asthma mortality epidemics, in: P. Davis (Ed), Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs (New York, Oxford University Press).
34. PHRMA (2004) Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results (Washington, Pharmaceutical Research and Manufacturers Association).
35. Pirmohamed, M. James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, British Medical Journal, 329, 30 July: pp. 15-19.
36. Rogers, A., Pilgrim, D. and Lacey. R. (1993) Experiencing Psychiatry: Users' Views of Services (London, Macmillan).
37. Shorter, E. (1997) A History of Psychiatry (New York, John Wiley).
38. Sudnow, D. (1965) Normal crimes: sociological features of the penal code in a public defender office, Social Problems, 12, pp. 255-276.